36results about How to "Scale up industrial production" patented technology

The invention relates to a super-capacitor electrode material and a preparation method thereof. A conventional commercial super-capacitor product still has lower energy density, but the greatest defect of low energy density of the super-capacitor is hopeful to be overcome and the energy density of a carbon nano tube/nickelous hydroxide/graphene composite material can be greatly improved if a carbon nano tube/nickelous hydroxide/graphene composite material with reasonable structure and composition can be manufactured due to the fact that nickelous hydroxide has a large pseudocapacitance value and good reversibility, graphene has a large specific surface area and excellent electrical conductivity, the nickelous hydroxide and the graphene are stacked in a layered manner and can generate an synergistic effect, and a small quantity of conductive carbon nano tubes are doped. The super-capacitor electrode material is a carbon nano tube/nickelous hydroxide/graphene composite prepared with a microwave method. According to the super-capacitor electrode material, micromolecular non-toxic and harmless ethylene glycol is adopted as a reaction medium, microwave heating is adopted to promote fast completion of a reaction, the reaction is finished in one pot, and the prepared composite has a large specific capacity and a large energy density.

The invention relates to the field of medicinal preparations, in particular to a taxol nanosuspension and a preparation method thereof. The taxol nanosuspension is characterized in that: a surfactant consists of poloxamer 188 and polyethylene glycol in a weight ratio of 1:1-1:3. According to the invention, the defects of low medicament loading rate, strong toxic or side effect, low stability, complex preparation process, high cost and the like in the conventional taxol preparation are overcome, and the technical breakthrough in the field is achieved; and the taxol nanosuspension has the advantages of increasing medicament content, reducing administration toxicity and production cost and improving the adaptability and compliance of a patient so as to realize clinical use.

The present invention relates to a method for purifying capsicine. It uses commercial capsaicine as raw material, and adopts the following steps: dissolving capsaicine in hydrophilic organic solvent,and making it implement complexation reaction with aqueous solution containing silver ion, then using hydrophobic organic solvent to treat silver ion complex, after the silver ion is removed, using alkali and acid to treat concentrate, finally, recovering high-purity capsicine.

The invention provides a Ramelteon sustained release preparation. The dosage form of the Ramelteon sustained release preparation is a tablet, a granule or a capsule. The Ramelteon sustained-release preparation comprises the following raw materials in parts by weight: 1 to 30 parts of Ramelteon, 50 to 250 parts of a filling agent, 5 to 50 parts of a sustained-release material and 0.2 to 10 parts of a lubricating agent; the sustained-release material is selected from at least one of hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, sodium alginate, calcium alginate, guar gum and xanthan gum; and the filling agent is selected from at least one of lactose, mannitol, sorbitol, cane sugar, microcrystalline cellulose and calcium hydrophosphate. The Ramelteon sustained release preparation can maintain enough drug concentration in a long time, prolongs the drug action time, and is completely dissolved out.

The invention relates to a three-high danshu capsule and a preparation process thereof. The three-high danshu capsule is characterized by comprising the following components in parts by weight: 10-20 parts of hawthorn, 8-15 parts of prepared multiflower knotweed root, 5-10 parts of cassia seed, 5-10 parts of rhizoma alismatis, 3-8 parts of ginseng, 3-8 parts of bulbus allii macrostemi and 5-10 parts of radix salviae miltiorrhizae; the preparation process comprises the following steps: (1) extracting the ginseng, the bulbus allii macrostemi and the radix salviae miltiorrhizae by ethanol, filtering an extract, recovering the ethanol from filtrate, decompressing and concentrating; (2) after extracting by the ethanol, adding water into the medicine residues of the ginseng, the bulbus allii macrostemi and the radix salviae miltiorrhizae, the hawthorn, prepared multiflower knotweed root, the cassia seed and the rhizoma alismatis, extracting, filtering, decompressing and concentrating the filtrate; (3) after concentrating, merging the ethanol extract and the water extract and concentrating continuously; (4) drying the extract in vacuum, pulverizing, sieving and storing dry powder after pulverizing for later use; (5) adding the auxiliary materials of talcum powder and magnesium stearate with a conventional quantity into the obtained extract powder and mixing; and (6) preparing the capsule. Experiments show that the three-high danshu capsule has a better health-care function of regulating blood fat and has no adverse reaction.

The present invention discloses one kind of nanometer iron catalyst and its preparation process. The nanometer iron catalyst is prepared through the following steps: preparing nanometer iron particle through introducing iron pentacarbonyl vapor into heated liquid medium via stirring to heat decompose iron pentacarbonyl, or heating the mixture of liquid medium and iron pentacarbonyl to heat decompose iron pentacarbonyl; cooling the mixture of nanometer iron particle and liquid medium, condensating and shunting to obtain nanometer iron catalyst. The present invention utilizes liquid medium to block the aggregation of iron particle for obtain nanometer iron particle and controls the quantity of iron pentacarbonyl vapor and the liquid medium and heating time to control the particle size. The nanometer iron catalyst has high activity, high dispersivity, high stability and simple industrial production process.

The invention discloses a brain-targeting nimodipine nano-suspension and a preparation method thereof. According to the preparation method, nimodipine serving as a model drug is subjected to ultrasonic supersonic coprecipitation and high pressure homogenization by using poloxamer 188 and tween 80 as stabilizing agents to prepare the brain-targeting nimodipine nano-suspension. The nano-suspension has a grain size of 200-230nm, a polydispersity index of 0.24+/-0.056 and Zeta electric potential of (-23.8+/-1.05)mV. The nano-suspension can be used for achieving the effect of brain-targeting administration by utilizing poloxamer and tween as the stabilizing agents.

The invention provides a Ramelteon quick-release and slow-release dual-release preparation. The Ramelteon quick-release and slow-release dual-release preparation comprises a quick-release part and a slow-release part; and the dosage form of the Ramelteon quick-release and slow-release double-release preparation is a double-layer tablet, a granule or a capsule, wherein the quick release part comprises the following raw materials in parts by weight: 1 to 30 parts of Ramelteon, 20 to 160 parts of a first filling agent, 0.5 to 10 parts of a disintegrating agent and 0.1 to 5 parts of a first lubricating agent; the slow-release part comprises the following raw materials in parts by weight: 1 to 30 parts of Ramelteon, 20 to 160 parts of a second filling agent, 5 to 30 parts of a sustained-release material and 0.2 to 10 parts of a second lubricating agent; the slow-release material is selected from at least one of hydroxypropyl methylcellulose, polyvinylpyrrolidone, hydroxypropyl cellulose, sodium alginate, calcium alginate, guar gum and xanthan gum. The preparation has a relatively high release speed in the initial stage, and meanwhile, the action time of the medicine can be prolonged.

The purpose of the present invention is to provide an anti-tumor disulfiram enteric-coated tablet with good stability, high bioavailability and little side effects by using modern pharmaceutical technology. The disulfiram enteric-coated tablet is composed of the following components in turn from the inside to the outside: a. a tablet core composed of disulfiram and pharmaceutically acceptable excipients; b. an intermediate isolation layer composed of an isolation material; c. an enteric-coated An enteric-coated layer composed of raw materials and pharmaceutically acceptable excipients; it is characterized in that: the tablet core is made of disulfiram bulk drug, diluent, and disintegrant that have been processed to increase solubility, and are directly compressed into tablets or made into granules before adding The disintegrating agent is compressed; wherein, the diluent is selected from one or more of LubriTose lactose series, sucrose, lactose, mannitol, precrossified starch, microcrystalline cellulose, and calcium carbonate in traditional excipients, and the dosage is 30% to 50% of the total weight of the tablet core; the disintegrant is selected from one or more of sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, and cross-linked povidone kind.

The invention discloses a method for preparing meliternin. The method comprises the steps as follows: taking melicope triphylla as a raw material, carrying out heat reflux extraction, two aqueous phase extraction, column chromatography under polyamide resin, and separating at high-speed counter-current chromatography, so as to obtain meliternin. The method disclosed by the invention is simple in operation, and high in yield and product purity.

The invention discloses a method for preparing carvedilol solid self-emulsifying sustained release tablets. The method comprises the steps of synthesizing hollow mesoporous silica with a uniform particles size and an obvious hollow structure; conducting liquid self-emulsifying with the drug-loaded hollow mesoporous silica as a solid carrier, so that carvedilol solid self-emulsifying particles are obtained; finally, evenly mixing the carvedilol solid self-emulsifying particles with proper auxiliary materials for wet granulation, and conducting tabletting to obtain the carvedilol solid self-emulsifying sustained release tablets. The preparing process is simple, operation is easy, and the cost is low. The prepared carvedilol solid self-emulsifying sustained release tablets have an obvious slow release effect and broad application prospects.

The invention discloses a pezopanib-quercetin eutectic crystal as well as a preparation method and application of the pezopanib-quercetin eutectic crystal. The eutectic crystal is formed by pezopanib and quercetin, and in an X-ray powder diffraction pattern obtained through Cu-K alpha radiation measurement, the eutectic crystal has characteristic diffraction peaks when the diffraction angles 2 theta are 5.3 degrees +/-0.2 degrees, 7.6 degrees +/-0.2 degrees, 12.6 degrees +/-0.2 degrees, 15.3 degrees +/-0.2 degrees, 17.7 degrees +/-0.2 degrees and 20.0 degrees +/-0.2 degrees. The pezopanib-quercetin eutectic crystal is good in stability, and does not generate crystal form transformation in at least 10 days under an accelerated condition (40 DEG C, 75% RH). The preparation method is simple, and industrial production can be amplified. Quercetin is introduced, so that the solubility of the pezopanib-quercetin eutectic crystal is obviously higher than that of a pezopanib monomer.